111 related articles for article (PubMed ID: 20148895)
1. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Li Y; Zhu X; Gu J; Dong D; Yao J; Lin C; Huang K; Fei J
Cancer Sci; 2010 Apr; 101(4):948-54. PubMed ID: 20148895
[TBL] [Abstract][Full Text] [Related]
2. miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
Gu J; Zhu X; Li Y; Dong D; Yao J; Lin C; Huang K; Hu H; Fei J
Med Oncol; 2011 Mar; 28(1):211-8. PubMed ID: 20143188
[TBL] [Abstract][Full Text] [Related]
3. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
Gao SM; Chen C; Wu J; Tan Y; Yu K; Xing CY; Ye A; Yin L; Jiang L
Biochem Biophys Res Commun; 2010 Dec; 403(2):203-8. PubMed ID: 21056550
[TBL] [Abstract][Full Text] [Related]
4. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis.
Li Y; Zhu X; Gu J; Hu H; Dong D; Yao J; Lin C; Fei J
Hematology; 2010 Aug; 15(4):215-21. PubMed ID: 20670480
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells.
Hu H; Li Y; Gu J; Zhu X; Dong D; Yao J; Lin C; Fei J
Leuk Lymphoma; 2010 Apr; 51(4):694-701. PubMed ID: 20141427
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
7. [Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21].
Li YM; Gu JY; Zhu XJ
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Feb; 30(2):170-3. PubMed ID: 20462046
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
9. hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide.
He JH; Li YM; Li YG; Xie XY; Wang L; Chun SY; Cheng WJ
Exp Ther Med; 2013 May; 5(5):1315-1321. PubMed ID: 23737871
[TBL] [Abstract][Full Text] [Related]
10. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
Han YH; Kim SZ; Kim SH; Park WH
Cancer Lett; 2008 Oct; 270(1):40-55. PubMed ID: 18539383
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
[TBL] [Abstract][Full Text] [Related]
13. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Ramos AM; Aller P
Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
[TBL] [Abstract][Full Text] [Related]
14. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Sengupta A; Banerjee D; Chandra S; Banerjee S
J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Lam HK; Li K; Chik KW; Yang M; Liu VC; Li CK; Fok TF; Ng PC; Shing MM; Chuen CK; Yuen PM
Int J Oncol; 2005 Aug; 27(2):537-45. PubMed ID: 16010437
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284
[TBL] [Abstract][Full Text] [Related]
19. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
20. The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
Guo Z; Meng M; Geng S; Du Z; Zheng Y; Yao J; Li Z; Han G; Lin H; Du G
J Ethnopharmacol; 2017 Jan; 196():29-38. PubMed ID: 27965050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
